{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T20:35:35Z","timestamp":1789850135086,"version":"4.0.1"},"reference-count":101,"publisher":"The Endocrine Society","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2013,4,1]]},"DOI":"10.1210\/jc.2012-4082","type":"journal-article","created":{"date-parts":[[2013,2,12]],"date-time":"2013-02-12T02:54:11Z","timestamp":1360637651000},"page":"1321-1332","source":"Crossref","is-referenced-by-count":74,"title":["The Use of Vaptans in Clinical Endocrinology"],"prefix":"10.1210","volume":"98","author":[{"given":"Alessandro","family":"Peri","sequence":"first","affiliation":[{"name":"Endocrine Unit, Center for Research, Transfer and High Education on Chronic, Inflammatory, Degenerative and Neoplastic Disorders for the Development of Novel Therapies, Department of Experimental and Clinical Biomedical Sciences, University of Florence, 50139 Florence, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","reference":[{"key":"key\n\t\t\t\t2019041113255190600_B1","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1093\/ndt\/gfi082","article-title":"Development of severe hyponatraemia in hospitalized patients: treatment-related risk factors and inadequate management","volume":"21","author":"Hoorn","year":"2006","journal-title":"Nephrol Dial Transplant"},{"key":"key\n\t\t\t\t2019041113255190600_B2","doi-asserted-by":"crossref","first-page":"2064","DOI":"10.1056\/NEJMcp066837","article-title":"Clinical practice. The syndrome of inappropriate antidiuresis","volume":"356","author":"Ellison","year":"2007","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t2019041113255190600_B3","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1185\/03007990802081675","article-title":"Epidemiology, clinical and economic outcomes of admission hyponatremia among hospitalized patients","volume":"24","author":"Zilberberg","year":"2008","journal-title":"Curr Med Res Opin"},{"key":"key\n\t\t\t\t2019041113255190600_B4","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1016\/j.amjmed.2009.01.027","article-title":"Mortality after hospitalization with mild, moderate, and severe hyponatremia","volume":"122","author":"Waikar","year":"2009","journal-title":"Am J Med"},{"key":"key\n\t\t\t\t2019041113255190600_B5","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1001\/archinternmed.2009.513","article-title":"Impact of hospital-associated hyponatremia on selected outcomes","volume":"170","author":"Wald","year":"2010","journal-title":"Arch Intern Med"},{"key":"key\n\t\t\t\t2019041113255190600_B6","doi-asserted-by":"crossref","first-page":"71.e1","DOI":"10.1016\/j.amjmed.2005.09.026","article-title":"Mild chronic hyponatremia is associated with falls, unsteadiness, and attention deficits","volume":"119","author":"Renneboog","year":"2006","journal-title":"Am J Med"},{"key":"key\n\t\t\t\t2019041113255190600_B7","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1677\/JOE-10-0050","article-title":"Chronic hyponatremia impairs memory in rats: effects of vasopressin antagonist tolvaptan","volume":"206","author":"Miyazaki","year":"2010","journal-title":"J Endocrinol"},{"key":"key\n\t\t\t\t2019041113255190600_B8","doi-asserted-by":"crossref","first-page":"275","DOI":"10.2215\/CJN.06120809","article-title":"Hyponatremia independent of osteoporosis is associated with fracture occurrence","volume":"5","author":"Kinsella","year":"2010","journal-title":"Clin J Am Soc Nephrol"},{"key":"key\n\t\t\t\t2019041113255190600_B9","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1359\/jbmr.090827","article-title":"Hyponatremia-induced osteoporosis","volume":"25","author":"Verbalis","year":"2010","journal-title":"J Bone Miner Res"},{"key":"key\n\t\t\t\t2019041113255190600_B10","doi-asserted-by":"crossref","first-page":"10864","DOI":"10.1074\/jbc.M110.155002","article-title":"Osteoclast response to low extracellular sodium and the mechanism of hyponatremia-induced bone loss","volume":"25","author":"Barsony","year":"2011","journal-title":"J Biol Chem"},{"key":"key\n\t\t\t\t2019041113255190600_B11","article-title":"2012 Chronic hyponatremia exacerbates multiple manifestations of senescence in male rats","author":"Barsony","journal-title":"Age (Dordr)"},{"key":"key\n\t\t\t\t2019041113255190600_B12","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1586\/erp.12.30","article-title":"Update on tolvaptan for the treatment of hyponatremia","volume":"12","author":"Dasta","year":"2012","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"key":"key\n\t\t\t\t2019041113255190600_B13","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.amjmed.2007.09.001","article-title":"Hyponatremia treatment guidelines 2007: expert panel recommendations","volume":"120","author":"Verbalis","year":"2007","journal-title":"Am J Med"},{"key":"key\n\t\t\t\t2019041113255190600_B14","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1007\/BF03346668","article-title":"Hyponatremia and the syndrome of inappropriate secretion of antidiuretic hormone (SIADH)","volume":"33","author":"Peri","year":"2010","journal-title":"J Endocrinol Invest"},{"key":"key\n\t\t\t\t2019041113255190600_B15","doi-asserted-by":"crossref","first-page":"S16","DOI":"10.1016\/S1521-690X(12)70004-0","article-title":"Considerations regarding the management of hyponatraemia secondary to SIADH","volume":"26","author":"Peri","year":"2012","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"key\n\t\t\t\t2019041113255190600_B16","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/S0025-7125(16)31523-1","article-title":"Hyponatremia","volume":"65","author":"Goldberg","year":"1981","journal-title":"Med Clin North Am"},{"key":"key\n\t\t\t\t2019041113255190600_B17","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1113\/jphysiol.1895.sp000565","article-title":"On the physiological action of extracts of pituitary body and certain other glandular organs: preliminary communication","volume":"18","author":"Oliver","year":"1895","journal-title":"J Physiol"},{"key":"key\n\t\t\t\t2019041113255190600_B18","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1084\/jem.3.2.245","article-title":"The physiological effects of extracts of the hypophysis cerebri and infundibular body","volume":"3","author":"Howell","year":"1898","journal-title":"J Exp Med"},{"key":"key\n\t\t\t\t2019041113255190600_B19","first-page":"1135","article-title":"Diabete insipido ed opoterapia","volume":"34","author":"Farini","year":"1913","journal-title":"Gazz Osped Clin"},{"key":"key\n\t\t\t\t2019041113255190600_B20","first-page":"2083","article-title":"Die Nierenvirkung von Hypophysenextracten beim Menschen","volume":"50","author":"Von Den Velden","year":"1913","journal-title":"Berl KlinWochenschr"},{"key":"key\n\t\t\t\t2019041113255190600_B21","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/S0021-9258(18)50947-9","article-title":"The purification and the amino acid content of vasopressin preparations","volume":"191","author":"Turner","year":"1951","journal-title":"J Biol Chem"},{"key":"key\n\t\t\t\t2019041113255190600_B22","doi-asserted-by":"crossref","first-page":"4751","DOI":"10.1021\/ja01647a089","article-title":"A synthetic preparation possessing biological properties associated with arginine-vasopressin","volume":"76","author":"du Vigneaud","year":"1954","journal-title":"J Am Chem Soc"},{"key":"key\n\t\t\t\t2019041113255190600_B23","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1126\/science.161.3838.280","article-title":"4-Leucine-oxytocin: natriuretic, diuretic, and antivasopressin polypeptide","volume":"161","author":"Chan","year":"1968","journal-title":"Science"},{"key":"key\n\t\t\t\t2019041113255190600_B24","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/S0022-3565(25)28652-9","article-title":"Natriuretic, diuretic and anti-arginine-vasopressin (ADH) effects of two analogs of oxytocin: [4-leucine]-oxytocin and [2,4-diisoleucine]-oxytocin","volume":"174","author":"Chan","year":"1970","journal-title":"J Pharmacol Exp Ther"},{"key":"key\n\t\t\t\t2019041113255190600_B25","first-page":"F165","article-title":"Antagonists of the antidiuretic activity of vasopressin","volume":"254","author":"Kinter","year":"1988","journal-title":"Am J Physiol"},{"key":"key\n\t\t\t\t2019041113255190600_B26","first-page":"207","article-title":"Species heterogeneity and antidiuretic hormone antagonists: what are the predictors?","volume-title":"Vasopressin: Cellular and Integrative Functions","author":"Allison","year":"1988"},{"key":"key\n\t\t\t\t2019041113255190600_B27","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/S0022-3565(25)22320-5","article-title":"SK&F 105494 is a potent antidiuretic hormone antagonist in the rhesus monkey (Macaca mulatta)","volume":"245","author":"Brooks","year":"1988","journal-title":"J Pharmacol Exp Ther"},{"key":"key\n\t\t\t\t2019041113255190600_B28","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1016\/S0022-3565(25)24092-7","article-title":"Evaluation of the pharmacologic properties of a vasopressin antagonist in Brattleboro rats","volume":"245","author":"Mah","year":"1988","journal-title":"J Pharmacol Exp Ther"},{"key":"key\n\t\t\t\t2019041113255190600_B29","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/S0022-3565(25)23405-X","article-title":"Cyclooxygenase inhibition unmasks the full antidiuretic agonist activity of the vasopressin antagonist, SK&F 101926, in dogs","volume":"249","author":"Albrightson-Winslow","year":"1989","journal-title":"J Pharmacol Exp Ther"},{"key":"key\n\t\t\t\t2019041113255190600_B30","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1126\/science.1850553","article-title":"OPC-21268, an orally effective, nonpeptide vasopressin V1 receptor antagonist","volume":"252","author":"Yamamura","year":"1991","journal-title":"Science"},{"key":"key\n\t\t\t\t2019041113255190600_B31","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1111\/j.1476-5381.1992.tb09058.x","article-title":"Characterization of a novel aquaretic agent, OPC-31260, as an orally effective, nonpeptide vasopressin V2 receptor antagonist","volume":"105","author":"Yamamura","year":"1992","journal-title":"Br J Pharmacol"},{"key":"key\n\t\t\t\t2019041113255190600_B32","doi-asserted-by":"crossref","first-page":"2653","DOI":"10.1172\/JCI116881","article-title":"Potent aquaretic agent. A novel nonpeptide selective vasopressin 2 antagonist (OPC-31260) in men","volume":"92","author":"Ohnishi","year":"1993","journal-title":"J Clin Invest"},{"key":"key\n\t\t\t\t2019041113255190600_B33","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1172\/JCI116554","article-title":"Biochemical and pharmacological properties of SR 49059, a new, potent, nonpeptide antagonist of rat and human vasopressin V1a receptors","volume":"92","author":"Serradeil-Le Gal","year":"1993","journal-title":"J Clin Invest"},{"key":"key\n\t\t\t\t2019041113255190600_B34","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/(SICI)1098-1128(199701)17:1<1::AID-MED1>3.0.CO;2-5","article-title":"Small molecule ligands for oxytocin and vasopressin receptors","volume":"17","author":"Freidinger","year":"1997","journal-title":"Med Res Rev"},{"key":"key\n\t\t\t\t2019041113255190600_B35","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/S0022-3565(24)36784-9","article-title":"Pharmacological profile of YM087, a novel potent nonpeptide vasopressin V1A and V2 receptor antagonist, in vitro and in vivo","volume":"282","author":"Tahara","year":"1997","journal-title":"J Pharmacol Exp Ther"},{"key":"key\n\t\t\t\t2019041113255190600_B36","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1016\/S0022-3565(24)37873-5","article-title":"OPC-41061, a highly potent human vasopressin V2-receptor antagonist: pharmacological profile and aquaretic effect by single and multiple oral dosing in rats","volume":"287","author":"Yamamura","year":"1998","journal-title":"J Pharmacol Exp Ther"},{"key":"key\n\t\t\t\t2019041113255190600_B37","doi-asserted-by":"crossref","first-page":"2397","DOI":"10.1016\/j.jacc.2006.08.039","article-title":"Emerging therapies for the management of decompensated heart failure: from bench to bedside","volume":"48","author":"de Goma","year":"2006","journal-title":"J Am Coll Cardiol"},{"key":"key\n\t\t\t\t2019041113255190600_B38","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1038\/nrendo.2010.229","article-title":"Vaptans for the treatment of hyponatremia","volume":"7","author":"Robertson","year":"2011","journal-title":"Nat Rev Endocrinol"},{"key":"key\n\t\t\t\t2019041113255190600_B39","doi-asserted-by":"crossref","first-page":"2145","DOI":"10.1210\/jc.2005-2287","article-title":"Efficacy and safety of oral conivaptan: a V1A\/V2 vasopressin receptor antagonist, assessed in a randomized, placebo-controlled trial in patients with euvolemic or hypervolemic hyponatremia","volume":"91","author":"Ghali","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"key":"key\n\t\t\t\t2019041113255190600_B40","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1097\/MAJ.0b013e31817b8148","article-title":"Efficacy and safety of oral conivaptan, a vasopressin-receptor antagonist, evaluated in a randomized, controlled trial in patients with euvolemic or hypervolemic hyponatremia","volume":"337","author":"Annane","year":"2009","journal-title":"Am J Med Sci"},{"key":"key\n\t\t\t\t2019041113255190600_B41","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1159\/000106456","article-title":"Assessment of the efficacy and safety of intravenous conivaptan in euvolemic and hypervolemic hyponatremia","volume":"27","author":"Zeltser","year":"2007","journal-title":"Am J Nephrol"},{"key":"key\n\t\t\t\t2019041113255190600_B42","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1053\/jhep.2003.50021","article-title":"A vasopressin receptor antagonist (VPA-985) improves serum sodium concentration in patients with hyponatremia: a multicenter, randomized, placebo-controlled trial","volume":"37","author":"Wong","year":"2003","journal-title":"Hepatology"},{"key":"key\n\t\t\t\t2019041113255190600_B43","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1056\/NEJMoa065181","article-title":"Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia","volume":"355","author":"Schrier","year":"2006","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t2019041113255190600_B44","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1681\/ASN.2009080857","article-title":"Oral tolvaptan is safe and effective in chronic hyponatremia","volume":"21","author":"Berl","year":"2010","journal-title":"J Am Soc Nephrol"},{"key":"key\n\t\t\t\t2019041113255190600_B45","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1016\/j.amjcard.2005.10.050","article-title":"Vasopressin v(2) receptor blockade with tolvaptan versus fluid restriction in the treatment of hyponatremia","volume":"97","author":"Gheorghiade","year":"2006","journal-title":"Am J Cardiol"},{"key":"key\n\t\t\t\t2019041113255190600_B46","doi-asserted-by":"crossref","first-page":"1884","DOI":"10.1056\/NEJMoa042743","article-title":"Nephrogenic syndrome of inappropriate antidiuresis","volume":"352","author":"Feldman","year":"2005","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t2019041113255190600_B47","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.2215\/CJN.00160106","article-title":"Successful long-term treatment of hyponatremia in syndrome of inappropriate antidiuretic hormone secretion with satavaptan (SR121463B), an orally active nonpeptide vasopressin V2-receptor antagonist","volume":"1","author":"Soupart","year":"2006","journal-title":"Clin J Am Soc Nephrol"},{"key":"key\n\t\t\t\t2019041113255190600_B48","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1111\/j.1365-2265.2007.03149.x","article-title":"Assessment of the efficacy and safety of intravenous conivaptan in patients with euvolaemic hyponatraemia: subgroup analysis of a randomized, controlled study","volume":"69","author":"Verbalis","year":"2008","journal-title":"Clin Endocrinol (Oxf)"},{"key":"key\n\t\t\t\t2019041113255190600_B49","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1093\/jjco\/hyq170","article-title":"Clinical implication of the antidiuretic hormone (ADH) receptor antagonist mozavaptan hydrochloride in patients with ectopic ADH syndrome","volume":"41","author":"Yamaguchi","year":"2011","journal-title":"Jpn J Clin Oncol"},{"key":"key\n\t\t\t\t2019041113255190600_B50","doi-asserted-by":"crossref","first-page":"2696","DOI":"10.1093\/annonc\/mdr431","article-title":"High sensitivity to tolvaptan in paraneoplastic syndrome of inappropriate ADH secretion (SIADH)","volume":"22","author":"Kenz","year":"2011","journal-title":"Ann Oncol"},{"key":"key\n\t\t\t\t2019041113255190600_B51","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1530\/EJE-10-1078","article-title":"Efficacy and safety of oral tolvaptan therapy in patients with the syndrome of inappropriate antidiuretic hormone secretion","volume":"164","author":"Verbalis","year":"2011","journal-title":"Eur J Endocrinol"},{"key":"key\n\t\t\t\t2019041113255190600_B52","doi-asserted-by":"crossref","first-page":"742","DOI":"10.2215\/CJN.06990711","article-title":"Efficacy and tolerance of urea compared with vaptans for long-term treatment of patients with SIADH","volume":"7","author":"Soupart","year":"2012","journal-title":"Clin J Am Soc Nephrol"},{"key":"key\n\t\t\t\t2019041113255190600_B53","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/S0002-9343(01)00678-7","article-title":"Long-term treatment of patients with inappropriate secretion of antidiuretic hormone by the vasopressin receptor antagonist conivaptan, urea, or furosemide","volume":"110","author":"Decaux","year":"2001","journal-title":"Am J Med"},{"key":"key\n\t\t\t\t2019041113255190600_B54","doi-asserted-by":"crossref","first-page":"2690","DOI":"10.1161\/01.CIR.0000070422.41439.04","article-title":"Vasopressin V2-receptor blockade with tolvaptan in patients with chronic heart failure: results from a double-blind, randomized trial","volume":"107","author":"Gheorghiade","year":"2003","journal-title":"Circulation"},{"key":"key\n\t\t\t\t2019041113255190600_B55","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1016\/j.jacc.2005.11.071","article-title":"Aquaretic effect of lixivaptan, an oral, non-peptide, selective V2 receptor vasopressin antagonist, in New York Heart Association functional class II and III chronic heart failure patients","volume":"47","author":"Abraham","year":"2006","journal-title":"J Am Coll Cardiol"},{"key":"key\n\t\t\t\t2019041113255190600_B56","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1080\/17482940701210179","article-title":"Improvement in hyponatremia during hospitalization for worsening heart failure is associated with improved outcomes: insights from the Acute and Chronic Therapeutic Impact of a Vasopressin Antagonist in Chronic Heart Failure (ACTIV in CHF) trial","volume":"9","author":"Rossi","year":"2007","journal-title":"Acute Card Care"},{"key":"key\n\t\t\t\t2019041113255190600_B57","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1001\/jama.297.12.1319","article-title":"Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial","volume":"297","author":"Konstam","year":"2007","journal-title":"JAMA"},{"key":"key\n\t\t\t\t2019041113255190600_B58","doi-asserted-by":"crossref","first-page":"2417","DOI":"10.1161\/hc4501.099313","article-title":"Acute hemodynamic effects of conivaptan, a dual V(1A) and V(2) vasopressin receptor antagonist, in patients with advanced heart failure","volume":"104","author":"Udelson","year":"2001","journal-title":"Circulation"},{"key":"key\n\t\t\t\t2019041113255190600_B59","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1016\/j.jacc.2008.08.013","article-title":"Acute hemodynamic effects of tolvaptan, a vasopressin V2 receptor blocker, in patients with symptomatic heart failure and systolic dysfunction: an international, multicenter, randomized, placebo-controlled trial","volume":"52","author":"Udelson","year":"2008","journal-title":"J Am Coll Cardiol"},{"key":"key\n\t\t\t\t2019041113255190600_B60","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1016\/j.ahj.2011.02.027","article-title":"Effects of tolvaptan on physician-assessed symptoms and signs in patients hospitalized with acute heart failure syndromes: analysis from the efficacy of vasopressin antagonism in heart failure outcome study with tolvaptan (EVEREST) trials","volume":"161","author":"Pang","year":"2011","journal-title":"Am Heart J"},{"key":"key\n\t\t\t\t2019041113255190600_B61","doi-asserted-by":"crossref","first-page":"415","DOI":"10.2459\/JCM.0b013e328355a740","article-title":"Efficacy of oral tolvaptan in acute heart failure patients with hypotension and renal impairment","volume":"13","author":"Vaduganathan","year":"2012","journal-title":"J Cardiovasc Med (Hagerstown)"},{"key":"key\n\t\t\t\t2019041113255190600_B62","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1093\/eurjhf\/hfq226","article-title":"Short- and long-term treatment of dilutional hyponatraemia with satavaptan, a selective arginine vasopressin V2-receptor antagonist: the DILIPO study","volume":"13","author":"Aronson","year":"2011","journal-title":"Eur J Heart Fail"},{"key":"key\n\t\t\t\t2019041113255190600_B63","doi-asserted-by":"crossref","first-page":"S19","DOI":"10.1007\/s10557-011-6303-y","article-title":"Effects of tolvaptan on volume overload in Japanese patients with heart failure: results of a phase II, multicenter, randomized, double-blind, placebo-controlled, parallel-group study","volume":"25","author":"Matsuzaki","year":"2011","journal-title":"Cardiovasc Drugs Ther"},{"key":"key\n\t\t\t\t2019041113255190600_B64","doi-asserted-by":"crossref","first-page":"S33","DOI":"10.1007\/s10557-011-6304-x","article-title":"Efficacy and safety of tolvaptan in heart failure patients with volume overload despite the standard treatment with conventional diuretics: a phase III, randomized, double-blind, placebo-controlled study (QUEST study)","volume":"25","author":"Matsuzaki","year":"2011","journal-title":"Cardiovasc Drugs Ther"},{"key":"key\n\t\t\t\t2019041113255190600_B65","doi-asserted-by":"crossref","first-page":"S57","DOI":"10.1007\/s10557-011-6349-x","article-title":"Phase III clinical pharmacology study of tolvaptan","volume":"25","author":"Inomata","year":"2011","journal-title":"Cardiovasc Drugs Ther"},{"key":"key\n\t\t\t\t2019041113255190600_B66","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1016\/j.cardfail.2011.08.012","article-title":"Renal effects of conivaptan, furosemide, and the combination in patients with chronic heart failure","volume":"17","author":"Goldsmith","year":"2011","journal-title":"J Card Fail"},{"key":"key\n\t\t\t\t2019041113255190600_B67","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1016\/j.cardfail.2011.08.005","article-title":"A multicenter, randomized, double-blind, placebo-controlled study of tolvaptan monotherapy compared to furosemide and the combination of tolvaptan and furosemide in patients with heart failure and systolic dysfunction","volume":"17","author":"Udelson","year":"2011","journal-title":"J Card Fail"},{"key":"key\n\t\t\t\t2019041113255190600_B68","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/S0009-9236(98)90107-2","article-title":"Therapeutic and diagnostic potential of a vasopressin-2 antagonist for impaired water handling in cirrhosis","volume":"63","author":"Inoue","year":"1998","journal-title":"Clin Pharmacol Ther"},{"key":"key\n\t\t\t\t2019041113255190600_B69","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1053\/jhep.2002.36375","article-title":"Pharmacodynamic effects of a nonpeptide antidiuretic hormone V2 antagonist in cirrhotic patients with ascites","volume":"36","author":"Guyader","year":"2002","journal-title":"Hepatology"},{"key":"key\n\t\t\t\t2019041113255190600_B70","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1111\/j.1365-2036.2010.04236.x","article-title":"Clinical trial: short-term effects of combination of satavaptan, a selective vasopressin V2 receptor antagonist, and diuretics on ascites in patients with cirrhosis without hyponatraemia\u2014a randomized, double-blind, placebo-controlled study","volume":"31","author":"Gin\u00e8s","year":"2010","journal-title":"Aliment Pharmacol Ther"},{"key":"key\n\t\t\t\t2019041113255190600_B71","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.jhep.2010.02.036","article-title":"Effects of a selective vasopressin V2 receptor antagonist, satavaptan, on ascites recurrence after paracentesis in patients with cirrhosis","volume":"53","author":"Wong","year":"2010","journal-title":"J Hepatol"},{"key":"key\n\t\t\t\t2019041113255190600_B72","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1007\/s00535-010-0240-6","article-title":"A multicenter, open-label, dose-ranging study to exploratively evaluate the efficacy, safety, and dose-response of tolvaptan in patients with decompensated liver cirrhosis","volume":"45","author":"Okita","year":"2010","journal-title":"J Gastroenterol"},{"key":"key\n\t\t\t\t2019041113255190600_B73","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1136\/gutjnl-2011-300157","article-title":"Satavaptan for the management of ascites in cirrhosis: efficacy and safety across the spectrum of ascites severity","volume":"61","author":"Wong","year":"2012","journal-title":"Gut"},{"key":"key\n\t\t\t\t2019041113255190600_B74","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1002\/hep.22293","article-title":"Effects of satavaptan, a selective vasopressin V(2) receptor antagonist, on ascites and serum sodium in cirrhosis with hyponatremia: a randomized trial","volume":"48","author":"Gin\u00e8s","year":"2008","journal-title":"Hepatology"},{"key":"key\n\t\t\t\t2019041113255190600_B75","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/j.jhep.2011.08.020","article-title":"Tolvaptan, an oral vasopressin antagonist, in the treatment of hyponatremia in cirrhosis","volume":"56","author":"C\u00e1rdenas","year":"2012","journal-title":"J Hepatol"},{"key":"key\n\t\t\t\t2019041113255190600_B76","article-title":"The use of an algorithm to aid diagnosis and treatment of patients with hyponatraemia secondary to SIADH","author":"Verbalis"},{"key":"key\n\t\t\t\t2019041113255190600_B77","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/S0002-9629(15)40736-0","article-title":"The urine\/plasma electrolyte ratio: a predictive guide to water restriction","volume":"319","author":"Furst","year":"2000","journal-title":"Am J Med Sci"},{"key":"key\n\t\t\t\t2019041113255190600_B78","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1634\/theoncologist.2011-0400","article-title":"Diagnosis and management of hyponatremia in cancer patients","volume":"17","author":"Castillo","year":"2012","journal-title":"Oncologist"},{"key":"key\n\t\t\t\t2019041113255190600_B79","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.lungcan.2009.05.015","article-title":"The occurrence of hyponatremia in SCLC and the influence on prognosis: a retrospective study of 453 patients treated in a single institution in a 10-year period","volume":"68","author":"Hansen","year":"2010","journal-title":"Lung Cancer"},{"key":"key\n\t\t\t\t2019041113255190600_B80","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1111\/j.1365-2796.1995.tb00907.x","article-title":"Syndrome of inappropriate secretion of antidiuretic hormone (SIADH) in malignant disease","volume":"238","author":"S\u00f8rensen","year":"1995","journal-title":"J Intern Med"},{"key":"key\n\t\t\t\t2019041113255190600_B81","doi-asserted-by":"crossref","first-page":"2438","DOI":"10.1016\/S0959-8049(97)00329-8","article-title":"Recurrent ifosfamide-induced hyponatraemia","volume":"33","author":"Kirch","year":"1997","journal-title":"Eur J Cancer"},{"key":"key\n\t\t\t\t2019041113255190600_B82","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1002\/(SICI)1096-911X(199808)31:2<129::AID-MPO21>3.0.CO;2-H","article-title":"Recurrence of SIADH after a high-dose regimen of thiotepa, carboplatin, and etoposide phosphate","volume":"31","author":"Kleta","year":"1998","journal-title":"Med Pediatr Oncol"},{"key":"key\n\t\t\t\t2019041113255190600_B83","article-title":"Hyponatremia in critical care patients: frequency, outcome, characteristics, and treatment with the vasopressin V(2)-receptor antagonist tolvaptan","author":"Friedman","journal-title":"J Crit Care"},{"key":"key\n\t\t\t\t2019041113255190600_B84","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1056\/NEJM200005253422107","article-title":"Hyponatremia","volume":"342","author":"Adrogu\u00e9","year":"2000","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t2019041113255190600_B85","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1038\/ki.1990.78","article-title":"Treating hyponatremia: damned if we do and damned if we don't","volume":"37","author":"Berl","year":"1990","journal-title":"Kidney Int"},{"key":"key\n\t\t\t\t2019041113255190600_B86","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1093\/ndt\/gfp731","article-title":"Intravenous conivaptan for the treatment of hyponatraemia caused by the syndrome of inappropriate secretion of antidiuretic hormone in hospitalized patients: a single-centre experience","volume":"25","author":"Velez","year":"2010","journal-title":"Nephrol Dial Transplant"},{"key":"key\n\t\t\t\t2019041113255190600_B87","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1111\/j.1365-2125.2011.04114.x","article-title":"Effects of CYP3A4 inhibition and induction on the pharmacokinetics and pharmacodynamics of tolvaptan, a non-peptide AVP antagonist in healthy subjects","volume":"73","author":"Shoaf","year":"2012","journal-title":"Br J Clin Pharmacol"},{"key":"key\n\t\t\t\t2019041113255190600_B88","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1007\/s00228-011-1106-4","article-title":"Effect of grapefruit juice on the pharmacokinetics of tolvaptan, a non-peptide arginine vasopressin antagonist, in healthy subjects","volume":"68","author":"Shoaf","year":"2012","journal-title":"Eur J Clin Pharmacol"},{"key":"key\n\t\t\t\t2019041113255190600_B89","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1177\/107424840501000304","article-title":"Tolvaptan administration does not affect steady state amiodarone concentrations in patients with cardiac arrhythmias","volume":"10","author":"Shoaf","year":"2005","journal-title":"J Cardiovasc Pharmacol Ther"},{"key":"key\n\t\t\t\t2019041113255190600_B90","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1177\/0091270010376193","article-title":"In vitro P-glycoprotein interactions and steady-state pharmacokinetic interactions between tolvaptan and digoxin in healthy subjects","volume":"51","author":"Shoaf","year":"2011","journal-title":"J Clin Pharmacol"},{"key":"key\n\t\t\t\t2019041113255190600_B91","doi-asserted-by":"crossref","first-page":"186","DOI":"10.3810\/pgm.2009.03.1991","article-title":"Economic impact of hyponatremia in hospitalized patients: a retrospective cohort study","volume":"121","author":"Callahan","year":"2009","journal-title":"Postgrad Med"},{"key":"key\n\t\t\t\t2019041113255190600_B92","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1681\/ASN.2007070752","article-title":"Medical costs of abnormal serum sodium levels","volume":"19","author":"Shea","year":"2008","journal-title":"J Am Soc Nephrol"},{"key":"key\n\t\t\t\t2019041113255190600_B93","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1751-7133.2010.00206.x","article-title":"Burden of sodium abnormalities in patients hospitalized for heart failure","volume":"17","author":"Shorr","year":"2011","journal-title":"Congest Heart Fail"},{"key":"key\n\t\t\t\t2019041113255190600_B94","doi-asserted-by":"crossref","first-page":"328","DOI":"10.2146\/ajhp100217","article-title":"Effect of serum sodium concentration and tolvaptan treatment on length of hospitalization in patients with heart failure","volume":"68","author":"Cyr","year":"2011","journal-title":"Am J Health Syst Pharm"},{"key":"key\n\t\t\t\t2019041113255190600_B95","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3810\/hp.2012.02.942","article-title":"Evaluation of costs associated with tolvaptan-mediated hospital length of stay reduction among US patients with the syndrome of inappropriate antidiuretic hormone secretion, based on SALT-1 and SALT-2 trials","volume":"40","author":"Dasta","year":"2012","journal-title":"Hosp Pract (Minneap)"},{"key":"key\n\t\t\t\t2019041113255190600_B96","doi-asserted-by":"crossref","first-page":"276","DOI":"10.3111\/13696998.2011.643329","article-title":"Evaluation of costs associated with tolvaptan-mediated length-of-stay reduction among heart failure patients with hyponatremia in the US, based on the EVEREST trial","volume":"15","author":"Chiong","year":"2012","journal-title":"J Med Econ"},{"key":"key\n\t\t\t\t2019041113255190600_B97","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1038\/ki.2011.78","article-title":"Vaptans are not the mainstay of treatment in hyponatremia: perhaps not yet","volume":"80","author":"Gross","year":"2011","journal-title":"Kidney Int"},{"key":"key\n\t\t\t\t2019041113255190600_B98","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1038\/nm935","article-title":"Inhibition of renal cystic disease development and progression by a vasopressin V2 receptor antagonist","volume":"9","author":"Gattone","year":"2003","journal-title":"Nat Med"},{"key":"key\n\t\t\t\t2019041113255190600_B99","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1038\/nm1004","article-title":"Effective treatment of an orthologous model of autosomal dominant polycystic kidney disease","volume":"10","author":"Torres","year":"2004","journal-title":"Nat Med"},{"key":"key\n\t\t\t\t2019041113255190600_B100","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1681\/ASN.2007060688","article-title":"Vasopressin directly regulates cyst growth in polycystic kidney disease","volume":"19","author":"Wang","year":"2008","journal-title":"J Am Soc Nephrol"},{"key":"key\n\t\t\t\t2019041113255190600_B101","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.1056\/NEJMoa1205511","article-title":"Tolvaptan in patients with autosomal dominant polycystic kidney disease","volume":"367","author":"Torres","year":"2012","journal-title":"N Engl J Med"}],"container-title":["The Journal of Clinical Endocrinology &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jcem\/article-pdf\/98\/4\/1321\/9044523\/jcem1321.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,29]],"date-time":"2025-04-29T20:40:05Z","timestamp":1745959205000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcem\/article\/98\/4\/1321\/2536650"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,4,1]]},"references-count":101,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2013,4,1]]}},"URL":"https:\/\/doi.org\/10.1210\/jc.2012-4082","relation":{},"ISSN":["0021-972X","1945-7197"],"issn-type":[{"value":"0021-972X","type":"print"},{"value":"1945-7197","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,4,1]]}}}